Amber Yasmeen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5958513/publications.pdf

Version: 2024-02-01

47 papers

1,100 citations

394421 19 h-index 32 g-index

47 all docs

47 docs citations

47 times ranked

1871 citing authors

#	Article	IF	CITATIONS
1	Induction of apoptosis by metformin in epithelial ovarian cancer: Involvement of the Bcl-2 family proteins. Gynecologic Oncology, 2011, 121, 492-498.	1.4	113
2	Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer. Gynecologic Oncology, 2014, 134, 607-614.	1.4	97
3	E6/E7 of HPV Type 16 Promotes Cell Invasion and Metastasis of Human Breast Cancer Cells. Cell Cycle, 2007, 6, 2038-2042.	2.6	83
4	Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors. BMC Cancer, 2017, 17, 638.	2.6	82
5	Targeting Insulin and Insulin-Like Growth Factor Pathways in Epithelial Ovarian Cancer. Journal of Oncology, 2010, 2010, 1-11.	1.3	56
6	Teucrium polium plant extract inhibits cell invasion and motility of human prostate cancer cells via the restoration of the E-cadherin/catenin complex. Journal of Ethnopharmacology, 2010, 129, 410-415.	4.1	43
7	Co-prevalence of Epstein–Barr virus and high-risk human papillomaviruses in Syrian women with breast cancer. Human Vaccines and Immunotherapeutics, 2016, 12, 1-4.	3.3	42
8	High-Risk HPV/ErbB-2 Interaction on E-Cadherin/Catenin Regulation in Human Carcinogenesis. Current Pharmaceutical Design, 2008, 14, 2159-2172.	1.9	39
9	Locking Src/Abl Tyrosine Kinase Activities Regulate Cell Differentiation and Invasion of Human Cervical Cancer Cells Expressing E6/E7 Oncoproteins of High-Risk HPV. Journal of Oncology, 2010, 2010, 1-10.	1.3	36
10	ErbB receptors and epithelial-cadherin–catenin complex in human carcinomas. Future Oncology, 2006, 2, 765-781.	2.4	34
11	Akt-Activated Endothelium Constitutes the Niche for Residual Disease and Resistance to Bevacizumab in Ovarian Cancer. Molecular Cancer Therapeutics, 2014, 13, 3123-3136.	4.1	29
12	Metformin Increases E-cadherin in Tumors of Diabetic Patients With Endometrial Cancer and Suppresses Epithelial-Mesenchymal Transition in Endometrial Cancer Cell Lines. International Journal of Gynecological Cancer, 2016, 26, 1213-1221.	2.5	29
13	BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide. Gynecologic Oncology, 2009, 115, 193-198.	1.4	28
14	Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors. BMC Cancer, 2015, 15, 817.	2.6	25
15	Clinical outcome of neoadjuvant chemotherapy for advanced ovarian cancer. Gynecologic Oncology, 2017, 144, 474-479.	1.4	25
16	Co-presence of human papillomaviruses and Epstein–Barr virus is linked with advanced tumor stage: a tissue microarray study in head and neck cancer patients. Cancer Cell International, 2020, 20, 361.	4.1	25
17	High-Risk HPVs and Human Carcinomas in the Syrian Population. Frontiers in Oncology, 2014, 4, 68.	2.8	23
18	ErbB-2 Receptor Cooperates with E6/E7 Oncoproteins of HPV Type 16 in Breast Tumorigenesis. Cell Cycle, 2007, 6, 2939-2943.	2.6	21

#	Article	IF	CITATIONS
19	The added value of sentinel node mapping in endometrial cancer. Gynecologic Oncology, 2020, 158, 84-91.	1.4	21
20	SMARCA4/2 loss inhibits chemotherapy-induced apoptosis by restricting IP3R3-mediated Ca2+ flux to mitochondria. Nature Communications, 2021, 12, 5404.	12.8	20
21	CAâ€125 reduction during neoadjuvant chemotherapy is associated with success of cytoreductive surgery and outcome of patients with advanced highâ€grade ovarian cancer. Acta Obstetricia Et Gynecologica Scandinavica, 2020, 99, 933-940.	2.8	19
22	Epstein–Barr virus and its association with Fascin expression in colorectal cancers in the Syrian population: A tissue microarray study. Human Vaccines and Immunotherapeutics, 2017, 13, 1573-1578.	3.3	16
23	<i>Elaeagnus angustifolia</i> Plant Extract Inhibits Angiogenesis and Downgrades Cell Invasion of Human Oral Cancer Cells via Erk1/Erk2 Inactivation. Nutrition and Cancer, 2018, 70, 297-305.	2.0	16
24	Critical role for D-type cyclins in cellular transformation induced by E6/E7 of human papillomavirus type 16 and E6/E7/ErbB-2 cooperation. Cancer Science, 2007, 98, 973-977.	3.9	15
25	Distinct homologous recombination gene expression profiles after neoadjuvant chemotherapy associated with clinical outcome in patients with ovarian cancer. Gynecologic Oncology, 2018, 148, 553-558.	1.4	15
26	Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis. Gynecologic Oncology, 2020, 156, 377-386.	1.4	14
27	Risk factors for lymph nodes involvement in obese women with endometrial carcinomas. Gynecologic Oncology, 2019, 155, 27-33.	1.4	13
28	Biguanides in combination with olaparib limits tumorigenesis of drugâ€resistant ovarian cancer cells through inhibition of Snail. Cancer Medicine, 2020, 9, 1307-1320.	2.8	13
29	High-risk human papillomaviruses and Epstein–Barr virus in breast cancer in Lebanese women and their association with tumor grade: a molecular and tissue microarray study. Cancer Cell International, 2021, 21, 308.	4.1	13
30	Dose dense carboplatin paclitaxel improves progression free survival in patients with endometrial cancer. Gynecologic Oncology, 2017, 147, 30-35.	1.4	11
31	Sequential therapeutic targeting of ovarian Cancer harboring dysfunctional BRCA1. BMC Cancer, 2019, 19, 44.	2.6	11
32	Identification of Predictive Biomarkers for Lymph Node Involvement in Obese Women With Endometrial Cancer. Frontiers in Oncology, 2021, 11, 695404.	2.8	10
33	Src inhibitors are promising therapy molecules for human cervical carcinomas. Medical Hypotheses, 2011, 77, 812-814.	1.5	9
34	Sentinel Lymph Node Sampling as an Alternative to Lymphadenectomy in Patients With Endometrial Cancer and Obesity. Journal of Obstetrics and Gynaecology Canada, 2021, 43, 1136-1144.e1.	0.7	8
35	Impact of lower uterine segment involvement in type II endometrial cancer and the unique mutational profile of serous tumors. Gynecologic Oncology Reports, 2018, 24, 43-47.	0.6	6
36	Copresence of High-Risk Human Papillomaviruses and Epstein–Barr Virus in Colorectal Cancer: A Tissue Microarray and Molecular Study from Lebanon. International Journal of Molecular Sciences, 2021, 22, 8118.	4.1	6

3

#	Article	IF	CITATIONS
37	Similar Overall Survival Using Neoadjuvant Chemotherapy or Primary Debulking Surgery in Patients Aged Over 75 Years with High-Grade Ovarian Cancer. Journal of Obstetrics and Gynaecology Canada, 2020, 42, 1339-1345.	0.7	5
38	Water-Pipe Smoking Exposure Deregulates a Set of Genes Associated with Human Head and Neck Cancer Development and Prognosis. Toxics, 2020, 8, 73.	3.7	5
39	Carboplatin plus paclitaxel weekly doseâ€dense chemotherapy for highâ€grade ovarian cancer: A reâ€evaluation. Acta Obstetricia Et Gynecologica Scandinavica, 2021, 100, 453-458.	2.8	5
40	Multi-omics data integration analysis identifies the spliceosome as a key regulator of DNA double-strand break repair. NAR Cancer, 2022, 4, zcac013.	3.1	5
41	Multiple lines of chemotherapy for patients with highâ€grade ovarian cancer: Predictors for response and effect on survival. International Journal of Cancer, 2021, 148, 2304-2312.	5.1	4
42	Outcome-Related Differences in Gene Expression Profiles of High-Grade Serous Ovarian Cancers Following Neoadjuvant Chemotherapy. Molecular Cancer Research, 2019, 17, 2422-2431.	3.4	3
43	The impact of wait times on oncological outcome in highâ€risk patients with endometrial cancer. Journal of Surgical Oncology, 2020, 122, 306-314.	1.7	3
44	Inhibition of Poly ADP-Ribose Glycohydrolase Sensitizes Ovarian Cancer Cells to Poly ADP-Ribose Polymerase Inhibitors and Platinum Agents. Frontiers in Oncology, 2021, 11, 745981.	2.8	3
45	Real-time continuous dielectrophoretic separation of malignant cells. , 2008, , .		1
46	Targeted sequencing of histologically defined serous endometrial cancer reflects prognosis and correlates with preoperative biopsy. Gynecologic Oncology Reports, 2019, 30, 100521.	0.6	0
47	E-Cadherin/Catenin Complex Modulations in Human Oral Cancer. , 2015, , 169-187.		O